Cooperation of mitochondrial and ER factors in quality control of tail-anchored proteins

  1. Verena Dederer
  2. Anton Khmelinskii
  3. Anna Gesine Huhn
  4. Voytek Okreglak
  5. Michael Knop
  6. Marius K Lemberg  Is a corresponding author
  1. University of Heidelberg, Germany
  2. Institute of Molecular Biology (IMB), Germany
  3. Calico Life Sciences LLC, United States

Abstract

Tail-anchored (TA) proteins insert post-translationally into the endoplasmic reticulum (ER), the outer mitochondrial membrane (OMM) and peroxisomes. Whereas the GET pathway controls ER-targeting, no dedicated factors are known for OMM insertion, posing the question of how accuracy is achieved. The mitochondrial AAA-ATPase Msp1 removes mislocalized TA proteins from the OMM, but it is unclear, how Msp1 clients are targeted for degradation. Here we screened for factors involved in degradation of TA proteins mislocalized to mitochondria. We show that the ER-associated degradation (ERAD) E3 ubiquitin ligase Doa10 controls cytoplasmic level of Msp1 clients. Furthermore, we identified the uncharacterized OMM protein Fmp32 and the ectopically expressed subunit of the ER-mitochondria encounter structure (ERMES) complex Gem1 as native clients for Msp1 and Doa10. We propose that productive localization of TA proteins to the OMM is ensured by complex assembly, while orphan subunits are extracted by Msp1 and eventually degraded by Doa10.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Verena Dederer

    Center for Molecular Biology of Heidelberg University (ZMBH), University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  2. Anton Khmelinskii

    Institute of Molecular Biology (IMB), Mainz, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0256-5190
  3. Anna Gesine Huhn

    Center for Molecular Biology of Heidelberg University (ZMBH), University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4798-4951
  4. Voytek Okreglak

    Calico Life Sciences LLC, South San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Michael Knop

    Center for Molecular Biology of Heidelberg University (ZMBH), University of Heidelberg, Heidelberg, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Marius K Lemberg

    Center for Molecular Biology of Heidelberg University (ZMBH), University of Heidelberg, Heidelberg, Germany
    For correspondence
    m.lemberg@zmbh.uni-heidelberg.de
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0996-1268

Funding

Deutsche Forschungsgemeinschaft (SFB1036/2 TP10)

  • Anton Khmelinskii

Deutsche Forschungsgemeinschaft (SFB1036/2 TP10)

  • Michael Knop

Deutsche Forschungsgemeinschaft (SFB1036/2 TP12)

  • Marius K Lemberg

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2019, Dederer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,369
    views
  • 903
    downloads
  • 76
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Verena Dederer
  2. Anton Khmelinskii
  3. Anna Gesine Huhn
  4. Voytek Okreglak
  5. Michael Knop
  6. Marius K Lemberg
(2019)
Cooperation of mitochondrial and ER factors in quality control of tail-anchored proteins
eLife 8:e45506.
https://doi.org/10.7554/eLife.45506

Share this article

https://doi.org/10.7554/eLife.45506

Further reading

    1. Cell Biology
    Kaili Du, Hongyu Chen ... Dan Li
    Research Article

    Niemann–Pick disease type C (NPC) is a devastating lysosomal storage disease characterized by abnormal cholesterol accumulation in lysosomes. Currently, there is no treatment for NPC. Transcription factor EB (TFEB), a member of the microphthalmia transcription factors (MiTF), has emerged as a master regulator of lysosomal function and promoted the clearance of substrates stored in cells. However, it is not known whether TFEB plays a role in cholesterol clearance in NPC disease. Here, we show that transgenic overexpression of TFEB, but not TFE3 (another member of MiTF family) facilitates cholesterol clearance in various NPC1 cell models. Pharmacological activation of TFEB by sulforaphane (SFN), a previously identified natural small-molecule TFEB agonist by us, can dramatically ameliorate cholesterol accumulation in human and mouse NPC1 cell models. In NPC1 cells, SFN induces TFEB nuclear translocation via a ROS-Ca2+-calcineurin-dependent but MTOR-independent pathway and upregulates the expression of TFEB-downstream genes, promoting lysosomal exocytosis and biogenesis. While genetic inhibition of TFEB abolishes the cholesterol clearance and exocytosis effect by SFN. In the NPC1 mouse model, SFN dephosphorylates/activates TFEB in the brain and exhibits potent efficacy of rescuing the loss of Purkinje cells and body weight. Hence, pharmacological upregulating lysosome machinery via targeting TFEB represents a promising approach to treat NPC and related lysosomal storage diseases, and provides the possibility of TFEB agonists, that is, SFN as potential NPC therapeutic candidates.

    1. Cell Biology
    2. Developmental Biology
    Sarah Y Coomson, Salil A Lachke
    Insight

    A study in mice reveals key interactions between proteins involved in fibroblast growth factor signaling and how they contribute to distinct stages of eye lens development.